Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.

Pasqualetti G, Ricci S, Dardano A, Ferdeghini M, Del Tacca M, Monzani F.

Mini Rev Med Chem. 2011 Aug;11(9):746-52. Review.

PMID:
21707530
[PubMed - indexed for MEDLINE]
2.

Sunitinib malate for the treatment of solid tumours: a review of current clinical data.

Motzer RJ, Hoosen S, Bello CL, Christensen JG.

Expert Opin Investig Drugs. 2006 May;15(5):553-61. Review.

PMID:
16634693
[PubMed - indexed for MEDLINE]
3.

Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.

Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, Rischin D.

Anticancer Drugs. 2008 Jun;19(5):547-52. doi: 10.1097/CAD.0b013e3282fc6cf7.

PMID:
18418222
[PubMed - indexed for MEDLINE]
4.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Hiles JJ, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661. Review.

PMID:
18192256
[PubMed - indexed for MEDLINE]
5.

Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.

Pasqualetti G, Ricci S, Boni G, Tognini S, Polini A, Mariani G, Ferdeghini M, Monzani F.

Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):171-6.

PMID:
22533521
[PubMed - indexed for MEDLINE]
6.

Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.

Kaldrymides P, Kostoglou-Athanassiou I, Gkountouvas A, Veniou E, Ziras N.

Endocrine. 2010 Feb;37(1):6-10. doi: 10.1007/s12020-009-9290-z. Epub 2010 Jan 6. Review.

PMID:
20963554
[PubMed - indexed for MEDLINE]
7.

Sunitinib: from rational design to clinical efficacy.

Chow LQ, Eckhardt SG.

J Clin Oncol. 2007 Mar 1;25(7):884-96. Review.

PMID:
17327610
[PubMed - indexed for MEDLINE]
8.

A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.

Bugalho MJ, Domingues R, Borges A.

Oncologist. 2009 Nov;14(11):1083-7. doi: 10.1634/theoncologist.2009-0195. Epub 2009 Nov 3.

PMID:
19887470
[PubMed - indexed for MEDLINE]
Free Article
9.

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.

Lin CI, Whang EE, Lorch JH, Ruan DT.

Surgery. 2012 Dec;152(6):1142-9. doi: 10.1016/j.surg.2012.08.016.

PMID:
23158184
[PubMed - indexed for MEDLINE]
10.

Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.

Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I.

Cancer Sci. 2011 Nov;102(11):1949-57. doi: 10.1111/j.1349-7006.2011.02054.x. Epub 2011 Sep 14. Review.

PMID:
21812860
[PubMed - indexed for MEDLINE]
11.

Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.

Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C.

J Clin Endocrinol Metab. 2014 Feb;99(2):498-509. doi: 10.1210/jc.2013-2574. Epub 2013 Nov 25.

PMID:
24276455
[PubMed - indexed for MEDLINE]
12.

Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.

Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.

J Oncol Pharm Pract. 2007 Mar;13(1):5-15. Review.

PMID:
17621562
[PubMed - indexed for MEDLINE]
13.

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Homet Moreno B, Garralda Cabanas E, Hitt R.

Clin Transl Oncol. 2010 Jul;12(7):468-72. doi: 10.1007/s12094-010-0539-z. Review.

PMID:
20615823
[PubMed - indexed for MEDLINE]
14.

Tyrosine kinase inhibitors and the thyroid.

Sherman SI.

Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):713-22. doi: 10.1016/j.beem.2009.08.001. Review.

PMID:
19942148
[PubMed - indexed for MEDLINE]
15.

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.

George S.

Curr Oncol Rep. 2007 Jul;9(4):323-7. Review.

PMID:
17588358
[PubMed - indexed for MEDLINE]
16.

Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.

Cabebe E, Wakelee H.

Drugs Today (Barc). 2006 Jun;42(6):387-98. Review.

PMID:
16845442
[PubMed - indexed for MEDLINE]
17.

Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.

Zhu AX, Duda DG, Sahani DV, Jain RK.

Cancer J. 2009 Jul-Aug;15(4):263-8. doi: 10.1097/PPO.0b013e3181af5e35. Review.

PMID:
19672141
[PubMed - indexed for MEDLINE]
18.

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D.

Cancer Chemother Pharmacol. 2008 Mar;61(3):515-24. Epub 2007 May 16.

PMID:
17505827
[PubMed - indexed for MEDLINE]
19.

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.

Grandinetti CA, Goldspiel BR.

Pharmacotherapy. 2007 Aug;27(8):1125-44. Review.

PMID:
17655513
[PubMed - indexed for MEDLINE]
20.

Early development of sunitinib in hepatocellular carcinoma.

Zhu AX, Raymond E.

Expert Rev Anticancer Ther. 2009 Jan;9(1):143-50. doi: 10.1586/14737140.9.1.143. Review.

PMID:
19105714
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk